Disease or Syndrome
Mendaera Secures $73M Series B Funding to Revolutionize Mainstream Medical Procedures with Robotics and AI
Mendaera, Series B funding, robotics, AI, medical procedures, healthcare technology, Threshold Ventures
BioMarin and CAMP4 Collaborate on RNA-Targeting Therapies for Rare Genetic Diseases
BioMarin, CAMP4, RNA-targeting therapies, genetic diseases, regulatory RNA, RAP Platform, antisense oligonucleotides, ASOs, rare genetic conditions
NHS England to Roll Out Eli Lilly’s Obesity Drug Mounjaro in Phased Approach
NHS England, Eli Lilly, Mounjaro, Obesity Drug, Phased Rollout, Weight Loss, Tirzepatide
Septerna Embarks on IPO Journey with Promising Preclinical Data and Vision to Revolutionize GPCR Drug Discovery
Septerna, IPO, GPCR, preclinical data, drug discovery, biotechnology, PTH1R agonists, hypoparathyroidism
Travere Therapeutics Pauses Phase 3 HARMONY Study Due to Manufacturing Scale-Up Challenges
Travere Therapeutics, Phase 3 HARMONY Study, Pegtibatinase, Classical Homocystinuria, Manufacturing Scale-Up Issue
CMS Prepares for Second Round of Medicare Drug Price Negotiation Program
Medicare Drug Price Negotiation Program, CMS, drug price negotiations, Inflation Reduction Act, Part D drugs, maximum fair prices (MFPs)
Remedee Labs Secures European Approval for Groundbreaking Fibromyalgia Wristband Therapy
Remedee Labs, fibromyalgia, wristband therapy, European approval, non-pharmaceutical treatment, millimeter-wave technology, endorphin stimulation
GE HealthCare’s Flyrcado (flurpiridaz F 18) PET Radiotracer Receives FDA Approval for Enhanced Detection of Coronary Artery Disease
GE HealthCare, Flyrcado, flurpiridaz F 18, PET radiotracer, Coronary artery disease (CAD), FDA approval, Cardiac imaging, Nuclear cardiology
Bristol Myers Squibb Invests $110 Million in T-Cell Therapy Pact with Prime Medicine
Bristol Myers Squibb (BMS), Prime Medicine, T-cell therapy, Ex vivo therapies, Biotech investment, Pharmaceutical partnerships
IGM Biosciences Undergoes Strategic Pivot to Autoimmune Diseases, Overhauls Leadership and Reduces Workforce
IGM Biosciences, autoimmune diseases, strategic pivot, T cell-engaging IgM antibodies, leadership changes, workforce reduction, imvotamab, IGM-2644